Researchers tracked nearly 1,000 SAVR patients, presenting eight-year data at the Heart Valve Society’s annual meeting in Cairo, Egypt. 

The 55-year-old patient woke up experiencing chest pain one morning and an ambulance was called. He was dead just a few hours later. His family's lawsuit argued that delays in care, communication errors and other issues were directly responsible for his death.

Coronary artery disease is both underdiagnosed and undertreated in women, and they often receive less guideline-recommended care than men. Why do these disparities persist? And what can today’s healthcare providers do to bring about change?

Cardiovascular Business is thrilled to unveil the Forty Under 40 Class of 2025.  

We asked readers to nominate individuals who are already making a major impact on the world of cardiovascular health at a young age. We wanted to hear about your best, your brightest, your most radical thinkers; the people who are never satisfied by something being “good enough” or “how it’s always been done.”   

TAVR is being used in more patients to treat severe aortic stenosis. However, according to a new commentary piece, SAVR is still the smartest treatment option for certain populations, including younger patients with bicuspid aortic valves.

Older heart failure patients with no immediate family are especially vulnerable. Additional interventions may be necessary to reach these patients and provide the best care possible.

Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.

As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.